Journal of Internal Medicine 1995: **238**: 563–566

Author Index

Ahlström H *see* Skogseid *et al.*
Ajubi N *see* Kroon *et al.*
Åkerström G *see* Skogseid *et al.*
Al-Bahrani A *see* Watts *et al.*
Amino N *see* Watanabe *et al.*
van Amstel H-KP *see* Lips *et al.*
Anaut P *see* Quiles *et al.*
Andersen MK *see* Sørensen *et al.*
Andía A *see* Quiles *et al.*
Angus HB *see* Crump *et al.*
Arneson T *see* Troein *et al.*
Aromaa A *see* Reunanen *et al.*
Arvastson B *see* Saxena *et al.*
Ascherio A, Willett WC. Metabolic and atherogenic effects of *trans* fatty acids (Editorial) 93
Asplund R. Sleep and hypnotics among the elderly in relation to body weight and somatic disease 65
van Asten WNJC *see* Kroon *et al.*

Bacourt F *see* Dralle *et al.*
Ballen JL *see* Boman *et al.*
Bard JM *see* Tonstad *et al.*
Baums J *see* Larsson *et al.*
Beard MEJ *see* Crump *et al.*
Beemer FA *see* Lips *et al.*
Beevers G *see* Lip *et al.*
Berends MJH *see* Lips *et al.*
Berglund BH *see* Hellénius *et al.*
Bergmark C *see* Nityanand *et al.*
Bergqvist D *see* Falke *et al.*
Berne C *see* Hallberg *et al.*
Berner M *see* Dralle *et al.*
Berntorp E *see* Florén *et al.*; Papadopoulos *et al.*
Björntorp P. Neuroendocrine ageing 401
Blijham GH *see* Lips *et al.*
Boëthius G *see* Larsson L *et al.*
Boman S, Ballen JL, Seggev JS. Dramatic responses to intravenous immunoglobulin in vasculitis 375
Bord III AE *see* Gagel RF *et al.*
Böttiger LE. Introduction–new horizons for medical ethics 509
Bradley A *see* Kumar *et al.*
Brandi ML *see* Modigliani *et al.*
Bregengård C *see* Myrup *et al.*
Brismar KE *see* Hellénius *et al.*
Bygren P *see* Saxena *et al.*

Calender A *see* Larsson *et al.*
Calender A, Giraud S, Cougard P, Chanson P, Lenoir G, Murat A, Hamon P, Proye C. Multiple endocrine neoplasia type 1 in France: clinical and genetic studies 263
Calmettes C *see* Modigliani *et al.*
Cameron D *see* Teh *et al.*
Cangir A *see* Gagel RF *et al.*
Cardinal J *see* Teh *et al.*
Carson E *see* Lagercrantz *et al.*
Chanson P *see* Calender *et al.*
Cibrián F *see* Quiles *et al.*
Constantini F *see* Schuchardt *et al.*
Cote GJ *see* Gagel *et al.*
Cougard P *see* Calender *et al.*; Raue *et al.*
Crovatto M *see* Mazzaro *et al.*
Crump JA, Beard MEJ, Angus HB, Fraser R, Hart DNJ, Nicholls MG. Acute adrenal insufficiency: a new presentation of Castleman's disease 81
Cummings T *see* Gagel *et al.*

D'Agati V *see* Schuchardt *et al.*
Derkx FHM *see* Nielsen *et al.*
Djøseland O *see* Tonstad *et al.*
Donehower LA *see* Kumar *et al.*
Donis-Keller H. The RET proco-oncogene and cancer 319
Dralle H *see* Modigliani *et al.*; Raue *et al.*
Dralle H, Scheumann GWF, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berner M, Niederle B, Vasens HFA. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study 357

Ellis T. Inflammatory bowel disease: genes or germs? 1
Elsborg L *see* Leotta *et al.*
Emanuelsson H. Future challenges to coronary angioplasty: perspectives on intracoronary imaging and physiology 111
Eng C *see* Mulligan *et al.*
Eriksson B *see* Skogseid *et al.*
Evans DB *see* Gagel *et al.*

Faber J *see* Myrup *et al.*
de Faire U *see* Lemne *et al.*; Nityanand *et al.*
de Faire UH *see* Hellénius *et al.*
Falke P, Mätzsch T, Sternby NH, Bergqvist D, Stavenow L. Intraplaque haemorrhage at carotid artery surgery – a predictor of cardiovascular mortality 131
Farnebo F *see* Larsson *et al.*
Feldberg MAM *see* Lips *et al.*
Florén C-H, Berntorp E, Hagstam K-E. Effects of low-density lipoprotein apheresis (dextran sulphate adsorption method) on bleeding tendency in treatment patients 559
Forgas L *see* Modigliani *et al.*
Forslud T, Hannonen P, Reitamo S, Fyhrquist F. Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels 71
Fraser R *see* Crump *et al.*
Fredrikson M *see* Lemne *et al.*
Friedman E *see* Lagercrantz *et al.*
Frilling A *see* Dralle *et al.*; Modigliani *et al.*; Mulligan *et al.*; Raue *et al.*
Frithz G *see* Ronquist *et al.*
Fruchart JC *see* Tonstad *et al.*
Fujikado T *see* Watanabe *et al.*
Fyhrquist F *see* Forslud *et al.*

Gagel RF *see* Mulligan *et al.*

© 1995 Blackwell Science Ltd

Gagel RF, Cote GJ, Martins Bugalho MJG, Bord III AE, Cummings T, Goepfert H, Evans DB, Cangir A, Khorana S, Schultz PN. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A 333
Gainzaráin J *see* Quiles *et al.*
Geerdink RA *see* Lips *et al.*
Georgiades A *see* Lemne *et al.*
Gervil M *see* Nygaard *et al.*
Gheri G *see* Dralle *et al.*
Gheri RG *see* Modigliani *et al.*
Gillett GR. Medical ethics in a multicultural context 531
van Gils APG *see* Lips *et al.*
Giraud S *see* Calender *et al.*; Larsson *et al.*
Gobl A *see* Lagercrantz *et al.*
Goepfert H *see* Gagel *et al.*
Gørbitz C *see* Tonstad *et al.*
Grama D *see* Skogseid *et al.*
Griese E-U *see* Mörike *et al.*
Grimmond S *see* Lagercrantz *et al.*; Larsson *et al.*

Hagstam K-E *see* Florén *et al.*
Hallberg A, Juhlin C, Berne C, Kämpe O, Karlsson FA. Islet cell antibodies: variable immunostaining of pancreatic islet cells and carcinoid tissue 207
Haller C, Salbach P, Katus H, Kübler W. Dr Haller's reply 185
Hamberger B *see* Nordenskjold M *et al.*
Hamon P *see* Calender *et al.*
Hannonen P *see* Forslud *et al.*
Hansen BM *see* Nygaard *et al.*
Hansen HH *see* Sørensen *et al.*
Hansen JM *see* Nygaard *et al.*
Hansson GK *see* Yokota *et al.*
Hart DNJ *see* Crump *et al.*
Hay ID *see* Heufelder *et al.*
Hayward NK *see* Lagercrantz *et al.*; Larsson *et al.*; Teh *et al.*
Hegedüs L *see* Nygaard *et al.*
Hellénius MB, Brismar KE, Berglund BH, de Faire UH. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men 121
Helmerhorst FM *see* Koster *et al.*
Henry JF *see* Dralle *et al.*
Heufelder AE, Hay ID. Further evidence for autoimmune mechanisms in the pathogenesis of Riedel's invasive fibrous thyroiditis 85
Hirsch J. The physician's role in the treatment of obesity 295
Hjalgrim H *see* Nygaard *et al.*
Hohshaku Y *see* Satoh *et al.*
Holm G *see* Klareskog *et al.*; Nityanand *et al.*
Hoogenboom H *see* Lips *et al.*
Höppener JWM *see* Lips *et al.*
Hulthén UL *see* Papadopoulos *et al.*

Iijima T *see* Watanabe *et al.*
Imaizumi T-A, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians 5
Iwatani Y *see* Watanabe *et al.*

Jansen-Schillhorn van Veen JM *see* Lips *et al.*
Jolore OMP. Refractory oedema in congestive heart failure: a contributory role of loop diuretics 184
Jönsson A *see* Papadopoulos *et al.*
Jorde R, Ytre-Arne K, Størmer J, Sundsfjord J. Short-term treatment of Graves' disease with methimazole in high versus low doses 161
Juhlin C *see* Hallberg *et al.*

Kadayifci A *see* Simsek *et al.*
Kahri J, Sane T, van Tol A, Taskinen M-R. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients 429
Kämpe O *see* Hallberg *et al.*
Karlsson FA *see* Hallberg *et al.*
Kashiwai T *see* Watanabe *et al.*
Katus H *see* Haller *et al.*
Khorana S *see* Gagel *et al.*
Klareskog L, Rönnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition 191
van der Kloot Meijburg HH. The hospital: battleground or meeting place? Ethical considerations regarding a fair distribution of new medical technologies 539
Knert P *see* Reunanen *et al.*
Koster T, Small R-A, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties 31
Kraimps JL *see* Raue *et al.*
Kroon AA, Ajubi N, van Asten WNJC, Stalenhoef AFH. The prevalence of peripheral vascular disease in familial hypercholesterolaemia 451
Kübler W *see* Haller *et al.*
Kubota K *see* Take *et al.*
Kuhlmann U *see* Mörike *et al.*
Kumar TR, Donehower LA, Bradley A, Matzuk MM. Transgenic mouse models for tumour suppressor genes 233
Kurabayashi H *see* Take *et al.*

Lacroix A *see* Mulligan *et al.*
Lagercrantz J, Larsson C, Grimmond S, Skogseid B, Gobl A, Friedman E, Carson E, Phelan C, Öberg K, Nordenskjöld M, Hayward NK, Weber G. Candidate genes for multiple endocrine neoplasia type 1 245
Landau BR *see* Luft *et al.*
Landsvater RM *see* Lips *et al.*
Larsson C *see* Lagercrantz *et al.*; Teh *et al.*
Larsson C, Calender A, Grimmond S, Giraud S, Hayward NK, Teh BT, Farnebo F. Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1 239
Larsson KS. The dissemination of false data through inadequate citation 445
Larsson L, Boëthius G. Differences in utilization of asthma drugs between two neighbouring Swedish provinces: relation to treatment in individuals with airway disease 307
Larsson L-G, Mudholkar GS, Baums J, Srivastava DK. Benefits and liabilities of hypermobility in the back pain disorders of industrial workers 461
Larsson-Blomberg L *see* Schuchardt *et al.*
Lefvert AK *see* Nityanand *et al.*
Lemne C, Lindvall K, Georgiades A, Fredrikson M, de Faire U,

Structural cardiac changes in relation to 24-h ambulatory blood pressure levels in borderline hypertension 49
Lenoir G *see* Calender *et al.*
Leotta SMG, Elsborg L. Localized tuberculosis of the oesophagus: a rare condition 77
Limbert E *see* Modigliani *et al.*; Raue *et al.*
Limbert F *see* Dralle *et al.*
Lindgren P-G *see* Skogseid *et al.*
Lindvall K *see* Lemne *et al.*
Lip GYH, Beevers G, Zarifis J. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint 389
Lips CJM *see* Mulligan *et al.*
Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham GH, Jansen-Schillhorn van Veen JM, Feldberg MAM, van Gils APG, Hoogenboom H, Berends MJH, Beemer FA, van Amstel H-KP, van Vroonhoven TJMV, Vroom TM. From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family 347
Llenas LF *see* Raue *et al.*
Lock S. Research ethics–a brief historical review to 1965 513
Lörelius L-E *see* Skogseid *et al.*
Luepker RV *see* Troein *et al.*
Luft R, Landau BR. Mitochondrial medicine 405

Machleidt C *see* Mörike *et al.*
McIntyre TM *see* Imaizumi *et al.*
Magadum S *see* Mörike *et al.*
Marsh DJ *see* Mulligan *et al.*
Martins Bugalho MJG *see* Gagel *et al.*
Måtzsch T *see* Falke *et al.*
Matzuk MM *see* Kumar *et al.*
Mazzaro C, Tulissi P, Moretti M, Mazzoran L, Pussini E, Crovatto M, Santini GF, Pozzato G. Clinical and virological findings in mixed cryoglobulinaemia 153
Mazzoran L *see* Mazzaro *et al.*
Mettang T *see* Mörike *et al.*
Mitropoulos KA *see* Watts *et al.*
Miyagi K *see* Satoh *et al.*
Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, Rosenberg-Bourgin M, Calmettes C, and the EuroMEN Study Group. Pheochromocytoma in multiple endocrine neoplasia type 2: European study 363
Mogensen CE *see* Nielsen *et al.*
Moretti M *see* Mazzaro *et al.*
Mörike K, Magadum S, Mettang T, Griese E-U, Machleidt C, Kuhlmann U. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy 469
Mudholkar GS *see* Larsson *et al.*
Mulligan LM, Marsh DJ, Robinson BG, Schuffenbecker I, Zedenius J, Lips CJM, Gagel RF, Takai S-I, Noll WW, Niederle B, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C. Genotype–phenotype correlation in multiple endocrine neoplasia-2: report of the International RET Mutation Consortium 343
Murat A *see* Calender *et al.*
Myrup B, Bregengård C, Faber J. Primary haemostasis in thyroid disease 59

Nicholls MG *see* Crump *et al.*
Niederle B *see* Dralle *et al.*; Modigliani *et al.*; Mulligan *et al.*; Raue *et al.*
Nielsen S, Schmitz A, Derkx FHM, Mogensen CE. Protenin and renal function in NIDDM patients with normo- and microalbuminuria 499
Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease 437
Noll WW *see* Mulligan *et al.*
Nordenskjöld M *see* Lagercrantz *et al.*
Nordenskjold M, Hamberger B, Oberg K. Advances in multiple endocrine neoplasia type 2 317
Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease 491

Öberg K *see* Lagercrantz *et al.*
Oberg K *see* Nordenskjold M *et al.*
Öberg K *see* Skogseid *et al.*
Ose L *see* Tonstad *et al.*
Owen JS *see* Watts *et al.*

Pachnis V *see* Schuchardt *et al.*
Papadopoulos KI, Jönsson A, Berntorp E, Törnquist C, Hulthén UL. Primary antiphospholipid syndrome associated with postoperative primary adrenal failure 175
Phelan C *see* Lagercrantz *et al.*
Pirie PL *see* Troein *et al.*
Ponder BAJ *see* Mulligan *et al.*
Pozzato G *see* Mazzaro *et al.*
Prescott SM *see* Imaizumi *et al.*
Proye C *see* Calender *et al.*; Dralle *et al.*; Raue *et al.*
Pussini E *see* Mazzaro *et al.*

Quiles I, Anaut P, Cibrián F, Gainzaráin J, Vega L, Andía A. Idiopathic CD4$^+$ T-lymphocytopenia with opportunistic infection and non-Hodgkin's lymphoma 184

Rastad J *see* Skogseid *et al.*
Råstam I *see* Troein *et al.*
Raue F *see* Mulligan *et al.*
Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A 369
Raue K *see* Modigliani *et al.*
Reeves BEA *see* Watts *et al.*
Reitamo S *see* Forslud *et al.*
Reunanen A, Takkunen H, Knert P, Seppänen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality 223
Riis P. Research ethics – a widening of the scope and extrapolation into the future 521
Robinson BG *see* Mulligan *et al.*
Rönnelid J *see* Klareskog *et al.*
Ronquist G *see* Waldenström *et al.*
Ronquist G, Soussi B, Frithz G, Scherstén T, Waldenström A. Disturbed energy balance in skeletal muscle of patients with untreated primary hypertension 167
Rosenberg-Bourgin M *see* Modigliani *et al.*

Rosendaal FR *see* Koster *et al.*
Rossner S *see* Ryttig *et al.*
Ryttig KR, Rossner S. Weight maintenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. A prospective, randomized, comparative, controlled long-term trial 299

Sakurai I *see* Satoh *et al.*
Salbach P *see* Haller *et al.*
Sane T *see* Kahri *et al.*
Santini GF *see* Mazzaro *et al.*
Satoh T, Sakurai I, Miyagi K, Hohshaku Y. Walking exercise and improved neuropsychological functioning in elderly patients with cardiac disease 423
Saxena R, Bygren P, Arvastson B, Wieslander J. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome 143
Scherstén T *see* Ronquist *et al.*
Scheumann GWF *see* Dralle *et al.*
Schmitz A *see* Nielsen *et al.*
Schuchardt A, D'Agati V, Larsson-Blomberg L, Constantini F, Pachnis V. RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis 327
Schuffenbecker I *see* Mulligan *et al.*
Schultz PN *see* Gagel *et al.*
Seggev JS *see* Boman *et al.*
Selander S *see* Troein *et al.*
Seppänen R *see* Reunanen *et al.*
Shepherd J *see* Teh *et al.*
Shirakura T *see* Take *et al.*
Simsek H, Kadayifci A. Absence of circulating antineutrophil cytoplasmic antibodies in familial Mediterranean fever 186
Skogseid B *see* Lagercrantz *et al.*
Skogseid B, Grama D, Rastad J, Eriksson B, Lindgren P-G, Ahlström H, Lörelius L-E, Wilander E, Åkerström G, Öberg K. Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1 281
Skogseid B, Öberg K. Experience with multiple endocrine neoplasia type 1 screening 255
Small R-A *see* Koster *et al.*
Søe-Jensen P *see* Nygaard *et al.*
Sørensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease 97
Soussi B *see* Ronquist *et al.*
Srivastava DK *see* Larsson *et al.*
Stafforini DM *see* Imaizumi *et al.*
Stalenhoef AFH *see* Kroon *et al.*
Stanley JM. Medical ethics–when to stop treatment 551
Stavenow L *see* Falke *et al.*
Sternby NH *see* Falke *et al.*
Størmer J *see* Jorde *et al.*
Sundsfjord J *see* Jorde *et al.*
Swedenborg J *see* Nityanand *et al.*

Takai S-I *see* Mulligan *et al.*
Take H, Kubota K, Tamura K, Kurabayashi H, Tamura J, Shirakura T. Acquired total immunoglobulin G deficiency in a patient with primary biliary cirrhosis 289
Takkunen H *see* Reunanen *et al.*
Tamura J *see* Take *et al.*
Tamura K *see* Take *et al.*
Taskinen M-R *see* Kahri *et al.*
Taskinen M-R. Postmenopausal hormone replacement therapy and plasma lipoproteins 384
Teh BT *see* Larsson *et al.*
Teh BT, Cardinal J, Shepherd J, Hayward NK, Weber G, Cameron D, Larsson C. Genetic mapping of the multiple endocrine neoplasia type 1 locus at 11q13 249
Thibodeau SN *see* Mulligan *et al.*
Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient 269

van Tol A *see* Kahri *et al.*
Tonstad S, Ose L, Gørbitz C, Djøseland O, Bard JM, Fruchart JC. Efficacy of sequential hormone replacement therapy in the treatent of hypercholestdrolaemia among postmenopausal women 39
Törnquist C *see* Papadopoulos *et al.*
Troein M, Arneson T, Råstam I, Pirie PL, Selander S, Luepker RV. Reported treatment of hypertension by family physicians in Sweden and Minnesota: a physician survey of practice habits 215
Tulissi P *see* Mazzaro *et al.*

Vasen HM *see* Modigliani *et al.*
Vasens HFA *see* Dralle *et al.*
Vega L *see* Quiles *et al.*
Vroom TM *see* Lips *et al.*
van Vroonhoven TJMV *see* Lips *et al.*

Waldenström A *see* Ronquist *et al.*
Waldenström A, Ronquist G. Ionophoric action on the cellular membrane as a pathophysiological mechanism in syndrome X: myth or reality? 187
Watanabe M, Iwatani Y, Kashiwai T, Iijima T, Fujikado T, Amino N. Euthyroid Graves' disease showing no thyroid abnormalities except positive thyroid-stimulating antibody (TSAb): two case reports 379
Watts GF, Mitropoulos KA, Al-Bahrani A, Reeves BEA, Owen JS. Lecithin-cholesterol acyltransferase deficiency presenting with acute pancreatitis: effect of infusion of normal plasma on triglyceride-rich lipoproteins 137
Weber G *see* Lagercrantz *et al.*; Teh *et al.*
Wieslander J *see* Saxena *et al.*
Wilander E *see* Skogseid *et al.*
Willett WC *see* Ascherio *et al.*

Yamada Y *see* Imaizumi *et al.*
Yokota T, Hansson GK. Immunological mechanisms in atherosclerosis 479
Ytre-Arne K *see* Jorde *et al.*
Yudkin JS. Coronary heart disease in diabetes mellitus: three new risk factors and a unifying hypothesis 21

Zarifis J *see* Lip *et al.*
Zedenius J *see* Mulligan *et al.*
Zimmerman GA *see* Imaizumi *et al.*

Journal of Internal Medicine 1995: **238**: 567–570

Subject Index

Abortion
  and mercury, false data, 445
Acromegaly
  in MEN-1, 239
Addison's disease
  antiphospholipid syndrome, 175
  interleukin-6 levels, 81
Adrenal failure
  antiphospholipid syndrome, 175
Ageing
  hypnotics and sleep disturbances, 65
  and mitochondria, 405
  neuroendocrine ageing and stress, 401
Albumin
  microalbuminaemia in diabetes, 21
Ambulatory blood pressure
  hypertension, 49
Anaemia
  autoimmune haemolytic, 175
Angina pectoris
  hypnotics, elderly people, 65
  syndrome X, 187
Angio-oedema
  ACE inhibitors, 179
Angioscopy
  coronary angioplasty, 111
Angiotensin-converting enzyme inhibitors
  angio-oedema, 179
Animal models
  Hirschsprung's disease, 327
Anti-HCV antibodies
  mixed cryoglogulinaemia, 153
Anticardiolipin antibodies
  Addison's disease, 175
Antidiuretic hormone
  SIADH in malignant disease, 97
Antineutrophil cytoplasmic antibodies
  familial Mediterranean fever, 185
Antinuclear antibodies
  in pulmonary renal syndrome, 143
Antiphospholipid syndrome
  primary adrenal failure, 175
Antithyroid drugs
  Graves' disease, 153
ApoA-I-containing lipoproteins, 429
Arrhythmias
  hypnotics, elderly people, 65
Asthma
  drug utilization, 307
  platelet-activating factor, 5
Atherogenesis
  trans fatty acids, 93
Atherosclerosis
  and hypercholesterolaemia, 451
  immunological mechanisms, 479
  lipoproteins in peripheral vascular disease, 437
  platelet-activating factor, 5
Atrial natriuretic peptide
  in rheumatoid arthritis, 71
Autoantibodies
  atherosclerosis, 437

Back pain
  hypermobility of spine, 461
Benefit–risk ratios
  venous thromboembolism and oral contraceptives, 31
Biliary cirrhosis
  primary, 289
Bleeding tendency
  LDL lipoprotein apheresis, 559
Blood pressure
  ambulatory, borderline hypertension, 49
Body mass index
  sleep and hypnotics, 65
  treatment of obesity, 299
Bronchofibroscopy, 179

Carcinoid tissue
  islet cell antibodies, 207
Cardiolipin antibodies
  endothelial cells, peripheral vascular disease, 437
Cardiovascular disease
  and hormone replacement therapy, 385, 389
  platelet-activating factor, 5
Carotid artery
  surgery, plaque haemorrhage and mortality, 131
Castleman's disease
  interleukin-6 levels, 81
Cerebral vasculitis
  i.v. immunoglobulin, 375
Cerebrovascular disease
  platelet-activating factor, 5
Cholesterol
  effects of coffee, 475
  hypercholesterolaemia, 451
  lecithin–cholesterol acyltransferase deficiency, 137
Cholesteryl ester transfer protein, 429
Coffee
  cholesterol-raising effects, 475
COPD
  asthma treatment, 307
Coronary angioplasty
  imaging modalities, 111
Coronary heart disease
  in diabetes mellitus, 21
  familial hypercholesterolaemia, 451
  and iron stores, 223
Cyclosporin A
  endothelin levels, 71
Cytokines
  rheumatoid arthritis, 191

© 1995 Blackwell Science Ltd

Dementia syndromes
  walking exercise, 423
Diabetes mellitus (IDDM)
  islet cell antibodies, 207
Diabetes mellitus (NIDDM)
  coronary heart disease, 21
  mitochondrial disease, 405
  platelet-activating factor, 5
  prorenin and renal function, 499
Diet
  and exercise, glucose tolerance, and insulin secretion, 121
  and iron stores, in CHD, 223
  VLCD, treatment of obesity, 295
Doppler spectrum analysis
  hypercholesterolaemia and peripheral vascular disease, 437
Doppler technique
  coronary angioplasty, 111
Dying
  assisted, 551

Endothelial cells
  cardiolipin antibodies, 437
Endothelins
  and cyclosporin A, hypertension, 71
Endotoxaemia
  platelet-activating factor, 5
Entactin
  pulmonary renal syndrome, 143
Ethics *see* Medical ethics; Research ethics
Exercise
  in cardiac disease, 423
  glucose tolerance, and insulin secretion, 121

Fatty acids
  (*trans* fatty acids) and atherogenesis, 93
France
  multiple endocrine neoplasia-1, genetic studies, 263
Free radicals
  oxidants and mitochondria, 405

Gastrinomas
  MEN-1, 269
Gastrointestinal disease
  platelet-activating factor, 5
Gemfibrozil
  treatment in hypertriglyceridaemia, 429
Genetic screening
  MEN-2, 333
Genetics
  inflammatory bowel disease, 1
Glomerulonephritis
  in pulmonary renal syndrome, 143
Glucose tolerance
  insulin, diet and exercise, 121
Glutamic acid decarboxylase, 207
Goitre, 491
  antithyroid drugs, 153
Goodpasture syndrome, 143
Graves' disease
  antithyroid drugs, 153
  radioiodine therapy, 491
  thyroid-stimulating antibody, 379

Haemostasis
  thyroid disease, 59
Heart failure
  congestive, refractory oedema, 184
Hepatitis B
  and polyarteritis nodosa, 375
Hepatitis C
  anti-HCV antibodies in mixed cryoglogulinaemia, 153
Hirschsprung's disease
  animal model, 327
Hormone replacement therapy
  and plasma lipoproteins, 385, 389
  sequential, 39
Hormones
  neuroendocrine ageing and stress, 401
Hypercholesterolaemia, 451
Hyperlipidaemia
  in sequential hormone replacement therapy, 39
Hypermobility of spine
  back pain in industrial workers, 461
Hyperparathyroidism
  multiple endocrine neoplasia-1, 269
  multiple endocrine neoplasia-2, 369
Hypertension
  ambulatory blood pressure, 49
  angio-oedema, 179
  and cyclosporin A, endothelin levels, 71
  platelet-activating factor, 5
  treatment issues, 215
  untreated, muscle bioenergenetics, 167
Hyperthyroidism, 491
  see also Graves' disease
Hypertriglyceridaemia
  acute pancreatitis, 137
  gemfibrozil treatment, 429
Hypnotics
  and sleep disturbances, 65
Hypothyroidism, 491
  in Graves' disease, 491

Imaging modalities
  coronary angioplasty, 111
Immunoglobulins
  IgG deficiency, 289
  i.v., in vasculitis, 375
Immunological mechanisms
  atherosclerosis, 479
Immunotherapy
  rheumatoid arthritis, 191
Industrial workers
  hypermobility of spine, 461
Inflammatory bowel disease
  genetics, 1
Inflammatory disorders
  platelet-activating factor, 5
Insulin
  glucose tolerance, diet and exercise, 121
  resistance, in sequential hormone replacement therapy, 39
Insulin-like growth factor-1, 121
Insulinoma
  MEN-1, 269

Interleukin-6
in Addison's disease, 81
Intrauterine growth
microalbuminaemia and nutrition, 21
Intravascular ultrasonography
coronary angioplasty, 111
Iron stores
in coronary heart disease, 223
Islet cell antibodies
IDDM, 207

Lecithin cholesteryl acyltransferase, 429
Lecithin–cholesterol acyltransferase deficiency, 137
Left ventricular hypertrophy
in borderline hypertension, 49
Lipolytic enzymes
hypertriglyceridaemia, 429
Lipoproteins
and hormone replacement therapy, 385, 389
LDL apheresis, effects on bleeding tendency, 559
peripheral vascular disease, 437
Liver disease
platelet-activating factor, 5

Major histocompatibility complex (MHC)
in rheumatoid arthritis, 191
Malignant disease
SIADH, 97
Medical ethics
history, 513
intellectual dishonesty, 509
multicultural context, 531
new technologies, 539
stopping treatment, 551
Mediterranean fever
antineutrophil cytoplasmic antibodies, 185
Mercury
and abortion, false data, 445
Meta-analysis
venous thromboembolism, and oral contraceptives, 31
Microalbuminaemia
in diabetes, 21
Microalbuminuria
NIDDM, 499
Mitochondrial diseases
and diabetes, 405
and neurodegenerative diseases, 405
Mixed cryoglogulinaemia
anti-HCV antibodies, 153
Multiple endocrine neoplasia-1
genetic studies
candidate genes, 245
France, 263
genetic mapping, 249
phospholipase C-β3 (PLCβ3), 245
tumour suppressor genes, 233
hyperparathyroidism in, 239, 269
pancreatic tumours, 255, 281
presymptomatic testing, 239
screening, 255
surgical management, 269, 281
trangenic mouse models, 233

Multiple endocrine neoplasia-2
2A, 333, 347
genotype–phenotype correlation, 343
hyperparathyroidism in, 369
management
presymptomatic treatment, 347
use of molecular information, 333
pheochromocytoma, 333, 363
RET proto-oncogene, 319
RET-deficient mice, 327
Muscle bioenergenetics
untreated hypertension, 167

Neurodegenerative diseases
mitochondria in, 405
Neuroendocrine ageing, 401
Neuroendocrine tumours *see* Multiple endocrine neoplasia-1
Neuropsychological functioning
walking exercise, 423
New technologies
medical ethics, 539
NMR spectroscopy
muscle bioenergenetics, 167
Non-Hodgkin's lymphoma
anti-HCV antibodies in mixed cryoglogulinaemia, 153
T-lymphocytopenia, 183

Obesity
treatment, 295
VLCD, 299
Oedema
angio-oedema, 179
refractory oedema, 184
Oesophageal tuberculosis, 77
Oestrogens
hormone replacement therapy, 385, 389
oestradiol, in sequential hormone replacement therapy, 39
Ophthalmopathy
thyroid-stimulating antibody, 379
Opportunistic Infections
non-Hodgkin's lymphoma, 183
Oral contraceptives
and venous thromboembolism, 31
Oxidants
and mitochondria, 405

Palliative care, 551
Palmoplantar pustulosis, 71
Pancreatic tumours
multiple endocrine neoplasia-1, 255, 281
Pancreatitis
lecithin–cholesterol acyltransferase deficiency, 137
Parathyroids
hyperparathyroidism, in multiple endocrine neoplasia-1, 269
Peripheral vascular disease
cardiolipin antibodies, 437
hypercholesterolaemia, 451
Pheochromocytoma
in MEN-2, 333, 363
Phosphocreatine
untreated hypertension, 167

Phospholipase C-β3 (PLCB)
MEN-1, 245
Phospholipid transfer protein, 429
Pituitary tumours
Rb gene, trangenic mouse models, 235
Plaque haemorrhage
and mortality, carotid artery surgery, 131
Plasminogen activator inhibitor
CHD in diabetes, 21
Platelet aggregation and agglutination
primary haemostasis, 59
Platelet-activating factor
synthesis and role in disease, 5
Polyarteritis nodosa
i.v. immunoglobulin, 375
Pregnancy
platelet-activating factor, 5
Progestins
hormone replacement therapy, 385, 389
Progestogen
in sequential hormone replacement therapy, 39
Proteinuria
lecithin–cholesterol acyltransferase deficiency, 137
PTCA *see* Coronary angioplasty
Pulmonary renal syndrome
ANCA, 143

Renal agenesis
animal model, 327
Renal disease
platelet-activating factor, 5
Renal function
prorenin in NIDDM, 499
Renin
renal function, 499
Research ethics
future prospects, 521
history, 513
RET proto-oncogene
multiple endocrine neoplasia-2, 319, 333
RET Mutation Consortium, 343
RET-deficient mice, MEN-2, 327
Rheumatoid arthritis
and cyclosporin A, 71
immunotherapy, 191
Riedel's thyroiditis, 85
Ristocetin
primary haemostasis, 59

Scientific data
false and misleading, 445
Septic shock
platelet-activating factor, 5
SIADH
in malignant disease, 97
Sleep disturbances
hypnotics, elderly people, 65
Smoking
platelet-activating factor, 5
Spine
hypermobility, back pain in industrial workers, 461
Stiffman syndrome
autoimmunity, 207
Stress
neuroendocrine ageing, 401
Stroke
plaque haemorrhage and mortality, 131
Syndrome X
angina pectoris, 187

T-lymphocytopenia
and non-Hodgkin's lymphoma, 183
Thrombocytopenia
anticardiolipin antibodies, 175
Thyroid disease
goitre, 491
hypothyroidism, in Graves' disease, 491
medullary thyroid carcinoma, 319, 347
lymph node dissection, 357
management, 333, 347
multicentre study, 357
pheochromocytoma, 333, 363
primary haemostasis, 59
Thyroid-stimulating antibody
ophthalmopathy, 379
Thyroiditis
Riedel's thyroiditis, 85
TIAs *see* Stroke
Trans-fatty acids
atherogenesis, 93
Tuberculosis
oesophageal, 77
Tumour suppressor genes
α-inhibin, 236
transgenic mouse models, 233
Tyrosine kinase receptor
MEN-2, 319

Ultrasonography
intravascular, coronary angioplasty, 111

Vasculitis
i.v. immunoglobulin, 375
Venous thromboembolism
and oral contraceptives, 31
von Willebrand's disease
primary haemostasis, 59

Walking exercise
and neuropsychological functioning, 423
Weight maintenance
VLCD, treatment of obesity, 299
Werner's syndrome, 231

Zollinger–Ellison syndrome
MEN-1, 269